Latest period
$6.90B
YoY change
-6.7%
5Y CAGR
+31.0%
Peak year (2024)
$8.40B
Cumulative CapEx
$67.58B
CapEx history chart for Eli Lilly (LLY) from 1989 to 2025
Latest: $7.84B
CapEx growth chart for Eli Lilly (LLY) from 1989 to 2025
Latest: -6.7%
CapEx history table for Eli Lilly (LLY) from 1989 to 2025
| 2025 | $7.84B | -6.7% | −$562.60M | ||
| 2024 | $8.40B | +13.7% | +$1.01B | ||
| 2023 | $7.39B | +147.6% | +$4.41B | ||
| 2022 | $2.99B | +50.9% | +$1.01B | ||
| 2021 | $1.98B | -2.5% | −$50.70M | ||
| 2020 | $2.03B | +49.9% | +$675.60M | ||
| 2019 | $1.35B | -55.2% | −$1.66B | ||
| 2018 | $3.02B | +39.5% | +$854.60M | ||
| 2017 | $2.16B | +98.1% | +$1.07B | ||
| 2016 | $1.09B | -32.8% | −$534.20M | ||
| 2015 | $1.63B | +3.9% | +$60.30M | ||
| 2014 | $1.57B | +43.2% | +$472.60M | ||
| 2013 | $1.09B | +4.7% | +$49.10M | ||
| 2012 | $1.04B | -38.3% | −$648.70M | ||
| 2011 | $1.69B | +42.7% | +$506.20M | ||
| 2010 | $1.19B | +38.8% | +$331.70M | ||
| 2009 | $855.00M | -9.7% | −$92.20M | ||
| 2008 | $947.20M | -12.5% | −$135.20M | ||
| 2007 | $1.08B | +0.4% | +$4.60M | ||
| 2006 | $1.08B | -17.0% | −$220.30M | ||
| 2005 | $1.30B | -31.6% | −$600.00M | ||
| 2004 | $1.90B | +11.2% | +$191.50M | ||
| 2003 | $1.71B | +50.9% | +$575.70M | ||
| 2002 | $1.13B | +27.9% | +$246.90M | ||
| 2001 | $884.00M | +30.4% | +$206.10M | ||
| 2000 | $677.90M | +28.3% | +$149.60M | ||
| 1999 | $528.30M | +25.8% | +$108.40M | ||
| 1998 | $419.90M | +14.6% | +$53.60M | ||
| 1997 | $366.30M | -17.5% | −$77.60M | ||
| 1996 | $443.90M | -19.5% | −$107.40M | ||
| 1995 | $551.30M | -4.4% | −$25.20M | ||
| 1994 | $576.50M | -9.0% | −$57.00M | ||
| 1993 | $633.50M | -36.8% | −$368.60M | ||
| 1992 | $1.00B | -12.3% | −$140.30M | ||
| 1991 | $1.14B | +13.4% | +$135.10M | ||
| 1990 | $1.01B | +81.7% | +$452.80M | ||
| 1989 | $554.50M | — | — |
- 2025$7.84B-6.7%
- 2024$8.40B+13.7%
- 2023$7.39B+147.6%
- 2022$2.99B+50.9%
- 2021$1.98B-2.5%
- 2020$2.03B+49.9%
- 2019$1.35B-55.2%
- 2018$3.02B+39.5%
- 2017$2.16B+98.1%
- 2016$1.09B-32.8%
- 2015$1.63B+3.9%
- 2014$1.57B+43.2%
- 2013$1.09B+4.7%
- 2012$1.04B-38.3%
- 2011$1.69B+42.7%
- 2010$1.19B+38.8%
- 2009$855.00M-9.7%
- 2008$947.20M-12.5%
- 2007$1.08B+0.4%
- 2006$1.08B-17.0%
- 2005$1.30B-31.6%
- 2004$1.90B+11.2%
- 2003$1.71B+50.9%
- 2002$1.13B+27.9%
- 2001$884.00M+30.4%
- 2000$677.90M+28.3%
- 1999$528.30M+25.8%
- 1998$419.90M+14.6%
- 1997$366.30M-17.5%
- 1996$443.90M-19.5%
- 1995$551.30M-4.4%
- 1994$576.50M-9.0%
- 1993$633.50M-36.8%
- 1992$1.00B-12.3%
- 1991$1.14B+13.4%
- 1990$1.01B+81.7%
- 1989$554.50M—
CapEx values are taken from Eli Lilly's reported cash flow statements (quarterly 10-Q and annual 10-K filings with the U.S. Securities and Exchange Commission). Each row shows the period end date and the filing date. YoY compares each figure to the same period one year earlier. Amounts are in USD as filed.
About CapEx at Eli Lilly (LLY)
According to Eli Lilly's latest reported financial statements, the company's current CapEx (TTM) is $6.90B. Capital expenditures (CapEx) are cash outlays for property, plant, and equipment and other long-lived productive assets — reported on the cash flow statement under investing activities. CapEx funds future capacity (factories, data centers, software, machinery), so rising spend can signal investment in growth, while heavy CapEx reduces free cash flow available to shareholders. We display CapEx as a positive amount (the absolute cash outflow); compare with revenue to gauge capital intensity and with total assets for the asset-base context.
Headline TTM above sums the four reported quarters through (reported ). Chart and table below cover the full reported history back to .
2025's annual CapEx for Eli Lilly (LLY) came in at $7.84B – declined 6.7% year-over-year.
Through 2020–2025 (5 years), Eli Lilly CapEx delivered a +31.0% annualised rate; with mixed annual results across the window.
Eli Lilly CapEx declined from $8.40B in 2024 to $7.84B in 2025, a 6.7% drawdown.
2024 marks the peak CapEx at $8.40B, with the historical low of $366.30M recorded in 1997.
Eli Lilly Capital Expenditures by Year
Eli Lilly Capital Expenditures 2025: $7.84B
Eli Lilly CapEx in 2025 was $7.84B, declined 6.7% below 2024.
Eli Lilly Capital Expenditures 2024: $8.40B
2024's CapEx for Eli Lilly came in at $8.40B, grew 13.7% from 2023. This figure represents the highest annual value in the available history.
Eli Lilly Capital Expenditures 2023: $7.39B
Eli Lilly posted CapEx of $7.39B in 2023, surged 147.6% from 2022.
Eli Lilly Capital Expenditures 2022: $2.99B
In 2022, Eli Lilly reported CapEx of $2.99B, surged 50.9% from 2021.
Eli Lilly Capital Expenditures 2021: $1.98B
Eli Lilly CapEx in 2021 was $1.98B.
See more financial history for Eli Lilly (LLY).
Sector peers by CapEx
Healthcare peers of Eli Lilly (LLY), ranked by their latest CapEx
| $14.05B | |
| $4.83B | |
| $4.11B | |
| $3.62B | |
| $2.81B | |
| $1.86B | |
| $1.52B | |
| $1.21B |
- $14.05B
- $4.83B
- $4.11B
- $3.62B
- $2.81B
- $1.86B
- $1.21B
Frequently asked questions
Eli Lilly (LLY) Key Financials
Charts, filings, and peer comparison for every metric
Explore more
Deep-dives across the income statement, cash flow, capital return, and valuation